Blood Eosinophils and Exhaled Nitric Oxide: Surrogate Biomarkers of Airway Eosinophilia in Stable COPD and Exacerbation
Abstract
:1. Introduction
2. Eosinophilic Airway Inflammation in COPD
3. Assessment of Eosinophilic Airway Inflammation Using FENO
4. Assessment of Eosinophilic Airway Inflammation Using Blood Eosinophils
5. Is It Worth Combining the Measurement of FENO and Blood Eosinophil Count?
6. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Barnes, P.J. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 2016, 138, 16–27. [Google Scholar] [CrossRef]
- Ritchie, A.I.; Wedzicha, J.A. Definition, Causes, Pathogenesis, and Consequences of Chronic Obstructive Pulmonary Disease Exacerbations. Clin. Chest Med. 2020, 41, 421–438. [Google Scholar] [CrossRef]
- MacLeod, M.; Papi, A.; Contoli, M.; Beghé, B.; Celli, B.R.; Wedzicha, J.A.; Fabbri, L.M. Chronic obstructive pulmonary disease exacerbation fundamentals: Diagnosis, treatment, prevention and disease impact. Respirology 2021, 26, 532–551. [Google Scholar] [CrossRef]
- Pavord, I.D. Biologics and chronic obstructive pulmonary disease. J. Allergy Clin. Immunol. 2018, 141, 1983–1991. [Google Scholar] [CrossRef]
- Brightling, C.E. Chronic obstructive pulmonary disease phenotypes, biomarkers, and prognostic indicators. Allergy Asthma Proc. 2016, 37, 432–438. [Google Scholar] [CrossRef]
- Barnes, P.J. Inflammatory endotypes in COPD. Allergy 2019, 74, 1249–1256. [Google Scholar] [CrossRef]
- Mathioudakis, A.G.; Janssens, W.; Sivapalan, P.; Singanayagam, A.; Dransfield, M.T.; Jensen, J.S.; Vestbo, J. Acute exacerbations of chronic obstructive pulmonary disease: In search of diagnostic biomarkers and treatable traits. Thorax 2020, 75, 520–527. [Google Scholar] [CrossRef]
- Leigh, R.; Pizzichini, M.M.; Morris, M.M.; Maltais, F.; Hargreave, F.E.; Pizzichini, E. Stable COPD: Predicting benefit from high-dose inhaled corticosteroid treatment. Eur. Respir. J. 2006, 27, 964–971. [Google Scholar] [CrossRef]
- Bafadhel, M.; McKenna, S.; Terry, S.; Mistry, V.; Reid, C.; Haldar, P.; McCormick, M.; Haldar, K.; Kebadze, T.; Duvoix, A.; et al. Acute exacerbations of chronic obstructive pulmonary disease: Identification of biologic clusters and their biomarkers. Am. J. Respir. Crit. Care Med. 2011, 184, 662–671. [Google Scholar] [CrossRef]
- Fujimoto, K.; Kubo, K.; Yamamoto, H.; Yamaguchi, S.; Matsuzawa, Y. Eosinophilic inflammation in the airway is related to glucocorticoid reversibility in patients with pulmonary emphysema. Chest 1999, 115, 697–702. [Google Scholar] [CrossRef]
- Brightling, C.E.; Monteiro, W.; Ward, R.; Parker, D.; Morgan, M.D.; Wardlaw, A.J.; Pavord, I.D. Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 2000, 356, 1480–1485. [Google Scholar] [CrossRef]
- Pizzichini, E.; Pizzichini, M.M.; Gibson, P.; Parameswaran, K.; Gleich, G.J.; Berman, L.; Dolovich, J.; Hargreave, F.E. Sputum eosinophilia predicts benefit from prednisone in smokers with chronic obstructive bronchitis. Am. J. Respir. Crit. Care Med. 1998, 158, 1511–1517. [Google Scholar] [CrossRef] [PubMed]
- Kolsum, U.; Donaldson, G.C.; Singh, R.; Barker, B.L.; Gupta, V.; George, L.; Webb, A.J.; Thurston, S.; Brookes, A.J.; McHugh, T.D.; et al. Blood and sputum eosinophils in COPD; relationship with bacterial load. Respir. Res. 2017, 18, 88. [Google Scholar] [CrossRef] [PubMed]
- Soter, S.; Barta, I.; Antus, B. Predicting sputum eosinophilia in exacerbations of COPD using exhaled nitric oxide. Inflammation 2013, 36, 1178–1185. [Google Scholar] [CrossRef]
- Tworek, D.; Antczak, A. Eosinophilic COPD—A distinct phenotype of the disease. Adv. Respir. Med. 2017, 85, 271–276. [Google Scholar] [CrossRef]
- Barnes, P.J.; Dweik, R.A.; Gelb, A.F.; Gibson, P.G.; George, S.C.; Grasemann, H.; Pavord, I.D.; Ratjen, F.; Silkoff, P.E.; Taylor, D.R.; et al. Exhaled nitric oxide in pulmonary diseases: A comprehensive review. Chest 2010, 138, 682–692. [Google Scholar] [CrossRef]
- Lu, Z.; Huang, W.; Wang, L.; Xu, N.; Ding, Q.; Cao, C. Exhaled nitric oxide in patients with chronic obstructive pulmonary disease: A systematic review and meta-analysis. Int. J. Chron. Obstruct. Pulmon. Dis. 2018, 13, 2695–2705. [Google Scholar] [CrossRef]
- Singh, D. Predicting corticosteroid response in chronic obstructive pulmonary disease. Blood eosinophils gain momentum. Am. J. Respir. Crit. Care Med. 2017, 196, 1098–1100. [Google Scholar] [CrossRef]
- Papaporfyriou, A.; Bakakos, P.; Hillas, G.; Papaioannou, A.I.; Loukides, S. Blood eosinophils in COPD: Friend or foe? Expert. Rev. Respir. Med. 2022, 16, 35–41. [Google Scholar] [CrossRef]
- Brightling, C.; Greening, N. Airway inflammation in COPD: Progress to precision medicine. Eur. Respir. J. 2019, 54, 1900651. [Google Scholar] [CrossRef]
- Roche, N.; Marthan, R.; Berger, P.; Chambellan, A.; Chanez, P.; Aguilaniu, B.; Brillet, P.Y.; Burgel, P.R.; Chaouat, A.; Devillier, P.; et al. Beyond corticosteroids: Future prospects in the management of inflammation in COPD. Eur. Respir. Rev. 2011, 20, 175–182. [Google Scholar] [CrossRef]
- Caramori, G.; Casolari, P.; Barczyk, A.; Durham, A.L.; Di Stefano, A.; Adcock, I. COPD immunopathology. Semin. Immunopathol. 2016, 38, 497–515. [Google Scholar] [CrossRef]
- Brandsma, C.A.; Van den Berge, M.; Hackett, T.L.; Brusselle, G.; Timens, W. Recent advances in chronic obstructive pulmonary disease pathogenesis: From disease mechanisms to precision medicine. J. Pathol. 2020, 250, 624–635. [Google Scholar] [CrossRef]
- Higham, A.; Quinn, A.M.; Cançado, J.E.D.; Singh, D. The pathology of small airways disease in COPD: Historical aspects and future directions. Respir. Res. 2019, 20, 49. [Google Scholar] [CrossRef]
- Antus, B.; Kardos, Z. Oxidative stress in COPD: Molecular background and clinical monitoring. Curr. Med. Chem. 2015, 22, 627–650. [Google Scholar] [CrossRef]
- Barnes, P.J. Oxidative Stress in chronic obstructive pulmonary disease. Antioxidants 2022, 11, 965. [Google Scholar] [CrossRef]
- Khoury, P.; Grayson, P.C.; Klion, A.D. Eosinophils in vasculitis: Characteristics and roles in pathogenesis. Nat. Rev. Rheumatol. 2014, 10, 474–483. [Google Scholar] [CrossRef]
- David, B.; Bafadhel, M.; Koenderman, L.; De Soyza, A. Eosinophilic inflammation in COPD: From an inflammatory marker to a treatable trait. Thorax 2021, 76, 188–195. [Google Scholar] [CrossRef]
- Papi, A.; Romagnoli, M.; Baraldo, S.; Braccioni, F.; Guzzinati, I.; Saetta, M.; Ciaccia, A.; Fabbri, L.M. Partial reversibility of airflow limitation and increased exhaled NO and sputum eosinophilia in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000, 162, 1773–1777. [Google Scholar] [CrossRef]
- Hogg, J.C.; Chu, F.; Utokaparch, S.; Woods, R.; Elliott, W.M.; Buzatu, L.; Cherniack, R.M.; Rogers, R.M.; Sciurba, F.C.; Coxson, H.O.; et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N. Engl. J. Med. 2004, 350, 2645–2653. [Google Scholar] [CrossRef]
- Hastie, A.T.; Martinez, F.J.; Curtis, J.L.; Doerschuk, C.M.; Hansel, N.N.; Christenson, S.; Putcha, N.; Ortega, V.E.; Li, X.; Barr, R.G.; et al. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: An analysis of the SPIROMICS cohort. Lancet Respir. Med. 2017, 5, 956–967. [Google Scholar] [CrossRef]
- Siva, R.; Green, R.H.; Brightling, C.E.; Shelley, M.; Hargadon, B.; McKenna, S.; Monteiro, W.; Berry, M.; Parker, D.; Wardlaw, A.J.; et al. Eosinophilic airway inflammation and exacerbations of COPD: A randomised controlled trial. Eur. Respir. J. 2007, 29, 906–913. [Google Scholar] [CrossRef] [PubMed]
- Antus, B.; Paska, C.; Barta, I. Predictive value of exhaled nitric oxide and blood eosinophil count in the assessment of airway eosinophilia in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2020, 15, 2025–2035. [Google Scholar] [CrossRef]
- Csoma, B.; Bikov, A.; Tóth, F.; Losonczy, G.; Müller, V.; Lázár, Z. Blood eosinophils on hospital admission for COPD exacerbation do not predict the recurrence of moderate and severe relapses. ERJ. Open Res. 2021, 7, 00543–2020. [Google Scholar] [CrossRef] [PubMed]
- Papi, A.; Bellettato, C.M.; Braccioni, F.; Romagnoli, M. Casolari, P.; Caramori, G.; Fabbri, L.M.; Johnston, S.L. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am. J. Respir. Crit. Care Med. 2006, 173, 1114–1121. [Google Scholar] [CrossRef] [PubMed]
- Horváth, I.; Barnes, P.J.; Loukides, S.; Sterk, P.J.; Högman, M.; Olin, A.C.; Amann, A.; Antus, B.; Baraldi, E.; Bikov, A.; et al. A European Respiratory Society technical standard: Exhaled biomarkers in lung disease. Eur. Respir. J. 2017, 49, 1600965. [Google Scholar] [CrossRef]
- Antus, B.; Horvath, I.; Barta, I. Assessment of exhaled nitric oxide by a new hand-held device. Respir. Med. 2010, 104, 1377–1380. [Google Scholar] [CrossRef]
- Alving, K.; Janson, C.; Nordvall, L. Performance of a new hand-held device for exhaled nitric oxide measurement in adults and children. Respir. Res. 2006, 7, 67. [Google Scholar] [CrossRef]
- Khalili, B.; Boggs, P.B.; Bahna, S.L. Reliability of a new hand-held device for the measurement of exhaled nitric oxide. Allergy 2007, 62, 1171–1174. [Google Scholar] [CrossRef]
- Taylor, D.R.; Pijnenburg, M.W.; Smith, A.D.; De Jongste, J.C. Exhaled nitric oxide measurements: Clinical application and interpretation. Thorax 2006, 61, 817–827. [Google Scholar] [CrossRef] [Green Version]
- Rutgers, S.R.; Meijer, R.J.; Kerstjens, H.A.; van der Mark, T.W.; Koëter, G.H.; Postma, D.S. Nitric oxide measured with single-breath and tidal-breathing methods in asthma and COPD. Eur. Respir. J. 1998, 12, 816–819. [Google Scholar] [CrossRef] [PubMed]
- Corradi, M.; Majori, M.; Cacciani, G.C.; Consigli, G.F.; de’Munari, E.; Pesci, A. Increased exhaled nitric oxide in patients with stable chronic obstructive pulmonary disease. Thorax 1999, 54, 572–575. [Google Scholar] [CrossRef] [PubMed]
- Clini, E.; Bianchi, L.; Pagani, M.; Ambrosino, N. Endogenous nitric oxide in patients with stable COPD: Correlates with severity of disease. Thorax 1998, 53, 881–883. [Google Scholar] [CrossRef] [PubMed]
- Lázár, Z.; Kelemen, Á.; Gálffy, G.; Losonczy, G.; Horváth, I.; Bikov, A. Central and peripheral airway nitric oxide in patients with stable and exacerbated chronic obstructive pulmonary disease. J. Breath. Res. 2018, 12, 036017. [Google Scholar] [CrossRef] [PubMed]
- Chou, K.T.; Su, K.C.; Huang, S.F.; Hsiao, Y.H.; Tseng, C.M.; Su, V.Y.; Hung, S.C.; Perng, D.W. Exhaled nitric oxide predicts eosinophilic airway inflammation in COPD. Lung 2014, 192, 499–504. [Google Scholar] [CrossRef] [PubMed]
- Chen, F.J.; Huang, X.Y.; Liu, Y.L.; Lin, G.P.; Xie, C.M. Importance of fractional exhaled nitric oxide in the differentiation of asthma-COPD overlap syndrome, asthma, and COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2016, 11, 2385–2390. [Google Scholar]
- Takayama, Y.; Ohnishi, H.; Ogasawara, F.; Oyama, K.; Kubota, T.; Yokoyama, A. Clinical utility of fractional exhaled nitric oxide and blood eosinophils counts in the diagnosis of asthma-COPD overlap. Int. J. Chron. Obstruct. Pulmon. Dis. 2018, 13, 2525–2532. [Google Scholar] [CrossRef]
- Dummer, J.F.; Epton, M.J.; Cowan, J.O.; Cook, J.M.; Condliffe, R.; Landhuis, C.E.; Smith, A.D.; Taylor, D.R. Predicting corticosteroid response in chronic obstructive pulmonary disease using exhaled nitric oxide. Am. J. Respir. Crit. Care Med. 2009, 180, 846–852. [Google Scholar] [CrossRef]
- Bhowmik, A.; Seemungal, T.A.; Donaldson, G.C.; Wedzicha, J.A. Effects of exacerbations and seasonality on exhaled nitric oxide in COPD. Eur. Respir. J. 2005, 26, 1009–1015. [Google Scholar] [CrossRef]
- Agusti, A.G.; Villaverde, J.M.; Togores, B.; Bosch, M. Serial measurements of exhaled nitric oxide during exacerbations of chronic obstructive pulmonary disease. Eur. Respir. J. 1999, 14, 523–528. [Google Scholar] [CrossRef]
- Antus, B.; Barta, I.; Horvath, I.; Csiszer, E. Relationship between exhaled nitric oxide and treatment response in COPD patients with exacerbations. Respirology 2010, 15, 472–477. [Google Scholar] [CrossRef]
- Global Initiative for Chronic Obstructive Lung Disease (GOLD). Available online: https://goldcopd.org/ (accessed on 10 June 2022).
- Antus, B.; Barta, I. Relationship between exhaled nitric oxide and the frequency of severe acute exacerbation of COPD: 3-year follow-up. Acta. Physiol. Hung. 2013, 100, 469–477. [Google Scholar] [CrossRef] [PubMed]
- Gao, J.; Zhang, M.; Zhou, L.; Yang, X.; Wu, H.; Zhang, J.; Wu, F. Correlation between fractional exhaled nitric oxide and sputum eosinophilia in exacerbations of COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2017, 12, 1287–1293. [Google Scholar] [CrossRef] [PubMed]
- Ferreira, I.M.; Hazari, M.S.; Gutierrez, C.; Zamel, N.; Chapman, K.R. Exhaled nitric oxide and hydrogen peroxide in patients with chronic obstructive pulmonary disease: Effects of inhaled beclomethasone. Am. J. Respir. Crit. Care Med. 2001, 164, 1012–1015. [Google Scholar] [CrossRef] [PubMed]
- Zietkowski, Z.; Kucharewicz, I.; Bodzenta-Lukaszyk, A. The influence of inhaled corticosteroids on exhaled nitric oxide in stable chronic obstructive pulmonary disease. Respir. Med. 2005, 99, 816–824. [Google Scholar] [CrossRef]
- Liu, J.; Sandrini, A.; Thurston, M.C.; Yates, D.H.; Thomas, P.S. Nitric oxide and exhaled breath nitrite/nitrates in chronic obstructive pulmonary disease patients. Respiration 2007, 74, 617–623. [Google Scholar] [CrossRef] [PubMed]
- Lim, C.S.; Rani, F.A.; Tan, L.E. Response of exhaled nitric oxide to inhaled corticosteroids in patients with stable COPD: A systematic review and meta-analysis. Clin. Respir. J. 2018, 12, 218–226. [Google Scholar] [CrossRef] [PubMed]
- Negewo, N.A.; McDonald, V.M.; Baines, K.J.; Wark, P.A.; Simpson, J.L.; Jones, P.W.; Gibson, P.G. Peripheral blood eosinophils: A surrogate marker for airway eosinophilia in stable COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2016, 11, 1495–1504. [Google Scholar] [CrossRef]
- Bafadhel, M.; Peterson, S.; De Blas, M.A.; Calverley, P.M.; Rennard, S.I.; Richter, K.; Fagerås, M. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: A post-hoc analysis of three randomised trials. Lancet Respir. Med. 2018, 6, 117–126. [Google Scholar] [CrossRef]
- Pascoe, S.; Pavord, I.; Hinds, D.; Locantore, N.; Barnes, N. The association between blood eosinophils and risk and treatment outcome in COPD is not dichotomised. Lancet Respir. Med. 2018, 6, e18. [Google Scholar] [CrossRef]
- Pascoe, S.; Barnes, N.; Brusselle, G.; Compton, C.; Criner, G.J.; Dransfield, M.T.; Halpin, D.M.G.; Han, M.K.; Hartley, B.; Lange, P.; et al. Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: Analysis of the IMPACT trial. Lancet Respir. Med. 2019, 7, 745–756. [Google Scholar] [CrossRef]
- Kreindler, J.L.; Watkins, M.L.; Lettis, S.; Tal-Singer, R.; Locantore, N. Effect of inhaled corticosteroids on blood eosinophil count in steroid-naïve patients with COPD. BMJ. Open Respir. Res. 2016, 3, e000151. [Google Scholar] [CrossRef] [PubMed]
- Mathioudakis, A.G.; Bikov, A.; Foden, P.; Lahousse, L.; Brusselle, G.; Singh, D.; Vestbo, J. Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD. Eur. Respir. J. 2020, 55, 1902119. [Google Scholar] [CrossRef] [PubMed]
- Landis, S.H.; Suruki, R.; Hilton, E.; Compton, C.; Galwey, N.W. Stability of blood eosinophil count in patients with COPD in the UK Clinical Practice Research Datalink. J. Chronic Obstr. Pulm. Dis. 2017, 14, 382–388. [Google Scholar] [CrossRef]
- Oshagbemi, O.A.; Burden, A.M.; Braeken, D.C.W.; Henskens, Y.; Wouters, E.F.M.; Driessen, J.H.M.; Maitland-van der Zee, A.H.; de Vries, F.; Franssen, F.M.E. Stability of blood eosinophils in patients with chronic obstructive pulmonary disease and in control subjects, and the impact of sex, age, smoking, and baseline counts. Am. J. Respir. Crit. Care Med. 2017, 195, 1402–1404. [Google Scholar] [CrossRef]
- Greulich, T.; Mager, S.; Lucke, T.; Koczulla, A.R.; Bals, R.; Fähndrich, S.; Jörres, R.A.; Alter, P.; Kirsten, A.; Vogelmeier, C.F.; et al. Longitudinal stability of blood eosinophil count strata in the COPD COSYCONET cohort. Int. J. Chron. Obstruct. Pulmon. Dis. 2018, 13, 2999–3002. [Google Scholar] [CrossRef]
- Singh, D.; Kolsum, U.; Brightling, C.E.; Locantore, N.; Agusti, A.; Tal-Singer, R.; ECLIPSE Investigators. Eosinophilic inflammation in COPD: Prevalence and clinical characteristics. Eur. Respir. J. 2014, 44, 1697–1700. [Google Scholar] [CrossRef]
- Southworth, T.; Beech, G.; Foden, P.; Kolsum, U.; Singh, D. The reproducibility of COPD blood eosinophil counts. Eur. Respir. J. 2018, 52, 1800427. [Google Scholar] [CrossRef]
- Casanova, C.; Celli, B.R.; de-Torres, J.P.; Martínez-Gonzalez, C.; Cosio, B.G.; Pinto-Plata, V.; de Lucas-Ramos, P.; Divo, M.; Fuster, A.; Peces-Barba, G.; et al. Prevalence of persistent blood eosinophilia: Relation to outcomes in patients with COPD. Eur. Respir. J. 2017, 50, 1701162. [Google Scholar] [CrossRef]
- Bafadhel, M.; McKenna, S.; Terry, S.; Mistry, V.; Pancholi, M.; Venge, P.; Lomas, D.A.; Barer, M.R.; Johnston, S.L.; Pavord, I.D.; et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: A randomized placebo-controlled trial. Am. J. Respir. Crit. Care Med. 2012, 186, 48–55. [Google Scholar] [CrossRef]
- Bafadhel, M.; Davies, L.; Calverley, P.M.; Aaron, S.D.; Brightling, C.E.; Pavord, I.D. Blood eosinophil guided prednisolone therapy for exacerbations of COPD: A further analysis. Eur. Respir. J. 2014, 44, 789–791. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Prins, H.J.; Duijkers, R.; Lutter, R.; Daniels, J.M.; van der Valk, P.; Schoorl, M.; Kerstjens, H.A.; van der Werf, T.S.; Boersma, W.G. Blood eosinophilia as a marker of early and late treatment failure in severe acute exacerbations of COPD. Respir. Med. 2017, 131, 118–124. [Google Scholar] [CrossRef] [PubMed]
- Bafadhel, M.; Greening, N.J.; Harvey-Dunstan, T.C.; Williams, J.E.; Morgan, M.D.; Brightling, C.E.; Hussain, S.F.; Pavord, I.D.; Singh, S.J.; Steiner, M.C. Blood eosinophils and outcomes in severe hospitalized exacerbations of COPD. Chest 2016, 150, 320–328. [Google Scholar] [CrossRef] [PubMed]
- Couillard, S.; Larivée, P.; Courteau, J.; Vanasse, A. Eosinophils in COPD exacerbations are associated with increased readmissions. Chest 2017, 151, 366–373. [Google Scholar] [CrossRef]
- MacDonald, M.I.; Osadnik, C.R.; Bulfin, L.; Hamza, K.; Leong, P.; Wong, A.; King, P.T.; Bardin, P.G. Low and high blood eosinophil counts as biomarkers in hospitalized acute exacerbations of COPD. Chest 2019, 156, 92–100. [Google Scholar] [CrossRef]
- Singh, D.; Wedzicha, J.A.; Siddiqui, S.; de la Hoz, A.; Xue, W.; Magnussen, H.; Miravitlles, M.; Chalmers, J.D.; Calverley, P.M.A. Blood eosinophils as a biomarker of future COPD exacerbation risk: Pooled data from 11 clinical trials. Respir. Res. 2020, 21, 240. [Google Scholar] [CrossRef]
- Çolak, Y.; Afzal, S.; Nordestgaard, B.G.; Marott, J.L.; Lange, P. Combined value of exhaled nitric oxide and blood eosinophils in chronic airway disease: The Copenhagen General Population Study. Eur. Respir. J. 2018, 52, 1800616. [Google Scholar] [CrossRef]
- Li, M.; Yang, T.; He, R.; Li, A.; Dang, W.; Liu, X.; Chen, M. The value of inflammatory biomarkers in differentiating asthma-COPD overlap from COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2020, 15, 3025–3037. [Google Scholar] [CrossRef]
- McDonald, V.M.; Fingleton, J.; Agusti, A.; Hiles, S.A.; Clark, V.L.; Holland, A.E.; Marks, G.B.; Bardin, P.P.; Beasley, R.; Pavord, I.D.; et al. Treatable traits: A new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report. Eur. Respir. J. 2019, 53, 1802058. [Google Scholar] [CrossRef]
- Cardoso, J.; Ferreira, A.J.; Guimarães, M.; Oliveira, A.S.; Simão, P.; Sucena, M. Treatable traits in COPD—A proposed approach. Int. J. Chron. Obstruct. Pulmon. Dis. 2021, 16, 3167–3182. [Google Scholar] [CrossRef]
FENO | Blood Eosinophils | |
---|---|---|
Difficulty for patients | requires cooperation | simple |
Availability of test | sporadic | universal |
Burden for patients | non-invasive | semi-invasive |
Methodology | standardized | standardized |
Results | immediate | within hours |
Reproducibility | good | good 1 |
Follow-up measurements | easy | easy |
Specificity for airway inflammation | high | low |
Confounding factors | smoking | co-morbidities |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Antus, B.; Barta, I. Blood Eosinophils and Exhaled Nitric Oxide: Surrogate Biomarkers of Airway Eosinophilia in Stable COPD and Exacerbation. Biomedicines 2022, 10, 2128. https://doi.org/10.3390/biomedicines10092128
Antus B, Barta I. Blood Eosinophils and Exhaled Nitric Oxide: Surrogate Biomarkers of Airway Eosinophilia in Stable COPD and Exacerbation. Biomedicines. 2022; 10(9):2128. https://doi.org/10.3390/biomedicines10092128
Chicago/Turabian StyleAntus, Balazs, and Imre Barta. 2022. "Blood Eosinophils and Exhaled Nitric Oxide: Surrogate Biomarkers of Airway Eosinophilia in Stable COPD and Exacerbation" Biomedicines 10, no. 9: 2128. https://doi.org/10.3390/biomedicines10092128